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Take home message: 
Responses to a palliative care survey from a clinical cohort of over 240 IPF patients were 
used to create a concise eleven-item distress measure that can help predict disease 
prognosis with similar reliability to lung function recordings. 
  
Abstract 
Idiopathic pulmonary fibrosis is a progressive and fatal interstitial lung disease. We 
aimed to determine if patient response to a palliative assessment survey could predict 
disease progression or death. 
We undertook a cross-sectional study in a UK clinical cohort of incident cases. Rasch-
based methodology provided a disease distress value from an abridged 11 item model of 
the original 45 item survey. Distress values were compared with measures of lung 
function. Disease progression or mortality alone was predicted at twelve months from 
survey completion, with risk of death assessed at three, six and twelve months. 
Disease distress values were negatively correlated with lung function (r=-0.275 percent 
predicted DLCO). Expected survey scores computed from distress values could 
distinguish disease progression, 8.8 (p=0.004), and people who died, 10.2 (p=0.002), 
from those who did not progress, 6.9. Actual survey scores predicted disease 
progression and mortality with an area under the curve of 0.60 and 0.64, respectively. 
Each point increment in actual score increased risk of twelve-month mortality by 10%, 
almost 43% of people scoring above 18 did not survive beyond 105 days. 
We define a short questionnaire that can score disease distress and predict prognosis, 
assisting clinical decision making in progressive fibrosis. 
1. Introduction 
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown 
aetiology, causing scarring of the lung, shortness of breath, cough and reduction in lung 
function. A UK study demonstrated an increase in incidence of IPF by 35% between 2000 
and 2008 , with higher incidence in men and older age groups [1]. Incidence and 
mortality continues to rise and is also increasing globally [2]. IPF is fatal with no current 
cure, though disease-modifying treatments are being introduced. In many cases, earlier 
palliative intervention could reduce the burden on the individual, as recommended in 
cancer care [3, 4], yet the variable natural history of IPF makes it difficult to predict care 
needs. 
The Sheffield Profile for Assessment and Referral to Care (SPARC) is a holistic needs 
tool, comprising 45 items across 9 domains, that can aid health professionals in 
identifying needs for palliative care [5]. Respondents find the questions easy to 
understand [6] and the tool has been adapted to international settings [7]. Such 
systematic assessment provides a useful indication of symptom distress [8]. Yet those 
who suffer chronic disease may not achieve the SPARC criteria for immediate clinical 
assessment, defined as a score of 3 in a single question, as habituation or affective 
comorbidity can affect symptom perception [5, 9, 10]. Regular completion of 45 items 
can be burdensome for those who suffer most [8], whilst self-assessment may result in 
interpatient differences despite the same underlying distress.  
Rasch-based methodology generates a scaled value for a set of responses as an 
interaction between question difficulty and the individuals’ likelihood of scoring. Initially 
used to standardise scholastic tests, extension of the Item Response Theory (IRT) class 
of models to allow multiple choice or graded options has found increased recognition in 
developing healthcare metrics and patient-reported outcomes [11-15]. Further 
advantages of the method enables question refinement, banking and assessment of the 
impact of demographics on item response [16-18]. 
We aimed to determine whether the SPARC could be used with IRT methodology to 
generate a tool that could appropriately distinguish disease progression in a UK clinical 
cohort of IPF patients [19, 20], helping to predict short-term prognosis.  
 
2. Methods 
The Prospective Observation of Fibrosis in Lung Clinical Endpoints (PROFILE) Central 
England (NCT01134822) study is a longitudinal observational clinical trial that has been 
described previously [19, 20]. Age was grouped at 65 or under, 66-79, 80 or over; 
comorbidities were grouped as none, 1-2, 3 or more. People were asked to complete the 
SPARC questionnaire, comprised of dichotomous items in two domains, as well as 
polytomous items in six domains (Supplementary Doc 1). 243 people from the PROFILE 
Central England study completed the SPARC and were subsequently included in the 
analysis.  
All analyses were performed in Stata (SE15.1). Lung function measures recorded at the 
initial SPARC assessment (±30 days) were used as baseline, with an outcome of disease 
progression within one year of SPARC completion defined as 10% relative decline in FVC 
or death. Percent predicted DLCO (%DLCO) and FVC (%FVC) was calculated using the 
suite of Global Lung Function Initiative (GLI) tools available from the European 
Respiratory Society [21]. Where %FVC (n=21) or %DLCO (n=75) could not be 
confirmed due to missing data, people were excluded from the relevant statistical 
analyses.  
A two-parameter graded response model was ultimately constructed with items showing 
good discrimination and model assumptions were verified [11, 22]. Parameters of 
discrimination and difficulty were assigned to each item (survey question) according to 
how well it could differentiate people across the scale of the underlying distress trait 
(theta), as well as the probability of a particular answer. Detailed information on the 
construct of the IRT model is provided as supplementary information; a final model of 11 
items was built, where larger theta values indicate more distress. (Supplementary Doc 
2; Supplementary Table 1; Supplementary Figure SF1).  
Pearson’s Correlation determined whether distress (theta) values correlated with %DLCO 
or %FVC measures. %DLCO was log transformed to meet normality assumptions. IRT 
test characteristic curves estimated expected questionnaire scores according to distress 
values calculated from the concise 11 item model, hereafter termed IPF Prognostic 
Assessment and Referral to Care (IPARC).  One-way ANOVA assessed differences in 
mean distress between categories of %DLCO (<40%, 40-60%, >60%). Two-way t-test 
assessed mean distress between those with disease progression and those without, 
whilst one-way ANOVA additionally assessed categories of disease progression (no 
disease progression, lung function decline only, death only). Tukey post-hoc analysis 
between categories was applied.  
We calculated the area under the Receiver Operator Characteristic (ROC) curve for the 
ability of the cumulative IPARC Score to predict disease progression within 12 months, 
as well as overall mortality compared with %FVC or %DLCO. The sensitivity and the 
specificity was compared using the chi-squared test [23]. 
Kaplan-Meier curves plotted time to disease progression, or overall mortality, against 
days since completing the questionnaire according to categories of IPARC Score. Cox 
regression estimated the hazard ratio (HR) of disease progression, as well as death in 
365 days (12 months), 180 days (6 months) and 90 days (3 months) according to 
increment or categories of IPARC Scores; lowest scorers as reference. The risk in 
comparison groups is contingent upon the proportion of the reference group that fails 
during the specified timescale. Analyses were initially univariate, and then adjusted for 
age, comorbidity, gender, and a significant interaction between age and comorbidity. 
Proportional hazard assumptions were checked using Schoenfeld residuals. 
3. Results 
Demographics 
From 243 people within the cohort, 103 (42.4%) had evidence of disease progression 
within one year, whilst 140 (57.6%) did not (Table 1). Of those with disease 
progression, 49 died within one year (47.6%). Within the disease progression subgroup, 
80.6% were male but no significant gender interaction was observed, similarly 
comorbidity count was not associated with progression. Those with disease progression 
had greater representation by ages 80 or over. We identified no significant relationships 
between communication and progression status, whilst we observe lower proportions 
with disease progression wanting information about personal finances. No relationship 
reached significance following Bonferroni correction. 
Table 1: Cohort demographics 
Outcome in 1 year: All 
No 
progression Progression (p value) 
  Number 243 140 103   
Gender (%)         
  Male 78.2 76.4 80.6   
  Female 21.8 23.6 19.4 0.438 
Age group (%)         
  65 and under 15.6 19.3 10.7   
  66 - 79 70.0 70.7 68.9   
  80 and over 14.4 10.0 20.4 0.026 
Comorbidity count (%)       
  None 23.9 26.4 20.4   
  1 to 2 47.7 49.3 45.6   
  3 or more 28.4 24.3 34.0 0.219 
Percentage (%) who were able to talk to:     
  Doctor 80.7 80.0 81.6 0.055 
  Community nurse 14.4 12.1 17.5 0.150 
  Hospital nurse 53.5 58.6 46.6 0.185 
  Religious advisor 2.9 2.1 3.9 0.360 
  Social worker 3.7 4.3 2.9 0.657 
  Family 65.0 67.1 62.1 0.977 
Percentage (%) who wanted more information on their:   
  Condition 28.8 32.9 23.3 0.206 
  Care 13.6 14.3 12.6 0.894 
  Treatment 18.1 21.4 13.6 0.185 
  Support 14.0 13.6 14.6 0.653 
  Finances 9.1 12.9 3.9 0.025 
Proportions include missing data. Missing values not presented, Chi-squared test p-
values based on non-missing data. Significant p-values before Bonferroni correction 
(p<0.05) in bold. P-value following correction p=0.0036. 
 
Disease distress is associated with lung function and disease progression 
A mild negative correlation was observed between distress values and baseline %FVC or 
%DLCO, indicating that higher distress correlated with worse lung function performance 
(Figure 1). The Pearson correlation coefficient for distress and %FVC was -0.267 
(p=0.0001), whilst for distress and %DLCO it was -0.275 (p=0.0003).  
The mean distress value according to severity of %DLCO was calculated and the IRT test 
characteristic curve estimated the expected score from the continuum of the distress 
values, calculated from the IPARC Score model. Mean distress values were significantly 
different according to severity of %DLCO (p=0.006). People with %DLCO <40% were 
significantly more distressed than those with a %DLCO >60% (p=0.004), leading to 
expected scores of 9.1 (θ=0.22) and 5.6 (θ=-0.38), respectively (Figure 2 A).  
Mean distress values were also significantly different according to disease progression 
(p=0.0085), where those who progressed had an expected score of 8.8 (θ=0.18) 
compared to an expected score of 6.9 for those who did not progress (θ=-0.14) (Figure 
2 B-i). Plotting mean distress of patients that died separately provided an expected score 
of 10.2 (θ=0.39); significance was identified across categories of disease progression 
(p=0.003), largely driven by the difference between those who died and those who did 
not progress (p=0.002) (Figure 2 Bii-iii). 
Lung function recordings require a suitable fitness to provide acceptable and repeatable 
measurements, introducing selection bias if individuals struggle to perform them. To 
understand the influence of missing data we evaluated distress according to completion 
of lung function (see Supplementary Table 2). Patients with missing %FVC data were 
more likely to have died (61.9%) than patients with complete %FVC data (16.2%; 
p<0.0001). However, there was no difference in mean distress between people with 
missing %FVC compared with complete data (p=0.384, compare scores 8.8 versus 7.6). 
Similarly, patients with missing %DLCO data were more likely to have died (34.7% 
versus 13.7%; p <0.0001), although those missing the data were also more distressed 
(p=0.002; compare scores 9.5 versus 7.0). In total, 75 people (31%) were missing 
DLCO measures; analyses based on non-missing DLCO recordings will underestimate 
actual effect sizes as they exclude a large sample of distressed patients. 
IPARC Score can predict disease progression and mortality 
Area under the curve (AUC) of the ROC curve initially assessed the ability of the IPARC 
Score to predict disease progression in the complete dataset (Figure 3), resulting in an 
AUC of 0.60 (95%CI: 0.53-0.68). ROC subsequently assessed the ability of the IPARC 
Score to predict death compared with lung function recordings in 167 people with 
complete data. We identified %DLCO as having the largest AUC of 0.83 (95%CI: 0.75-
0.91), whilst %FVC had an AUC of 0.66 (95%CI: 0.56-0.76). The cumulative IPARC 
Score provided an AUC of 0.64 (95%CI: 0.52-0.77); a minimum score of 9 resulted in 
59.2% sensitivity and 62.9% specificity. No statistical difference was observed between 
the AUC of IPARC Score and %FVC (p=0.8), although %DLCO was significantly better at 
predicting mortality (p=0.013). Ability of IPARC Score to predict mortality was also 
assessed independently from lung function recordings in the complete dataset (see 
Supplementary Figure SF2), resulting in a greater AUC of 0.66 (95%CI: 0.57-0.74). 
Kaplan Meier curves of time to event were plotted separately for disease progression and 
death according to observed IPARC Score (Figure 4), categorised using expected score 
from mean distress where % DLCO <40% (score of 9). A large proportion of people 
scoring over 18 from the 11 IPARC items had rapid disease progression, 51.5% of people 
scoring at least 9 progressed within one year. Fewer than 75% of people who scored 
between 9 and 18 survived 365 days (Figure 4 B). A total of 101 people scored 9 or 
more and 29 died within 365 days, providing a positive predictive value of 28.7%; this is 
compared with 20 people from the 142 scoring 8 or less, 14.1%. Scoring over 18 
increased the positive predictive value to 42.9% from a total of 14 people, all deaths in 
this group occurred within 105 days. 
Cox regression estimates of the risk of disease progression and risk of death in one year 
for each unit increment of the IPARC Score are reported in Table 2. For every point 
increase, the risk of disease progression increased by 5% (HR 1.05 95%CI 1.02-1.09) 
whilst risk of death increased by 10% (HR 1.10 95%CI 1.05-1.15). Disease progression 
was almost 60% more likely for people scoring 9-18 (HR 1.59 95%CI 1.04-2.44), 
compared to those scoring less, whilst those scoring highest were at three times the risk 
(HR 3.19 95%CI 1.53-6.64). People scoring between 9 and 18 were more than twice as 
likely to die within 365 days as those scoring less than 9 (HR 2.43 95%CI 1.30-4.55). 
Estimates for those scoring over 18 did not meet proportional hazard assumptions at 
365 days, although their risk of death in 180 days was 12 fold that of those scoring less 
than 9 (HR 12.32 95%CI 3.84-39.55), whilst the risk for those scoring between 9 and 18 
more than doubled (HR 2.82 95%CI 1.03-7.68). Similar results were estimated at 90 
days for those scoring highest (HR 19.47 95%CI 1.98-191.13), though scoring between 
9 and 18 was not statistically different from scoring less (HR 7.69 95%CI 0.89-66.28).  
Table 2. Cox regression risk estimates of disease progression and overall 
mortality by IPARC Score. 
    Number % fail HR 95%CI HR* 95%CI* 
365 day disease progression risk         
  IPARC Score 243 42.39% 1.05 (1.01-1.08) 1.05 (1.02-1.09) 
          
  IPARC category       
  Score 0-8 142 35.92% 1  1   
  Score 9-18 87 49.43% 1.50 (1.00-2.26) 1.59 (1.04-2.44) 
  Score 19-33 14 64.29% 2.69 (1.32-5.47) 3.19 (1.53-6.64) 
365 day mortality risk           
  IPARC Score 243 20.16% 1.08 (1.03-1.12) 1.10 (1.05-1.15) 
          
  IPARC category       
  Score 0-8 142 14.08% 1  1   
  Score 9-18 87 26.44% 2.02 (1.11-3.68) 2.43 (1.30-4.55) 
  Score 19-33 14 42.86% 4.44 (1.78-11.08) †5.74 (2.20-14.97) 
180 day mortality risk           
  IPARC category       
  Score 0-8 142 4.93% 1  1   
  Score 9-18 87 11.49% 2.43 (0.92-6.37) 2.82 (1.03-7.68) 
  Score 19-33 14 42.86% 11.69 (3.92-34.86) 12.32 (3.84-39.55) 
90 day mortality risk           
  IPARC category       
  Score 0-8 142 0.70% 1  1   
  Score 9-18 87 5.75% 8.37 (0.98-71.61) 7.69 (0.89-66.28) 
  Score 19-33 14 21.43% 34.25 (3.56-329.37) 19.47 (1.98-191.13) 
*adjusted for age group, comorbidity count, gender, age comorbidity interaction. 
Proportional hazard assumptions met unless stated (†). HR: hazard ratio 
 
A sub-analysis was performed on a small sample who had an IPARC score before and 
after pirfenidone treatment to preliminarily assess therapy modification of the IPARC 
score (Supplementary Figure SF3). Overall, in 12 patients with matched scores taken at 
a year interval, there was a non-significant trend towards increased distress following 
therapy with pirfenidone. The change in level of distress with treatment was driven by 
the IPARC category prior to therapy; patients scoring under 9 (mild distress) 
demonstrated more distress following therapy (p=0.0086), whilst those scoring 9 or over 
(high level of distress) had a more varied response including some reduction in IPARC 
score. 
 
 
 
 
 
 
4. Discussion 
The SPARC questionnaire is recognised within the UK National Health Service as a way to 
help address and improve end-of-life care management [5, 6, 9, 24]. We have utilised a 
unique clinical cohort of patients with IPF [19], determining that items specified within 
the IPARC list can identify patients at high risk of death within 3-6 months, providing 
opportunity for earlier supportive care and improving patient outcomes (Box 1).  
 
Box 1: Scoring of items in final model  
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  7 1  Shortness of breath 0 1 2 3   
  13 2  Feeling weak 0 1 2 3   
  14 3  Feeling tired 0 1 2 3   
  16 4  Feeling sleepy in the day 0 1 2 3   
  17 5  Loss of appetite 0 1 2 3   
  21 6  Feeling restless and agitated 0 1 2 3   
  22 7  Uncontrolled symptoms 0 1 2 3   
  41 8  Side effects of treatment 0 1 2 3   
  34 9  Losing independence 0 1 2 3   
  35 10  Ability to carry out daily activities 0 1 2 3   
  36 11  Ability to carry out household tasks 0 1 2 3   
                 
     TOTAL  
 
<9       9-18      >18   
                    
Items from final model presented. Highest scores, 19 or above, may be considered an indicator 
for follow-up within three months; intermediate scores, 9-18, support review within six months; 
lower scores, <9, support review within 12 months. 
 
We use Item Response Theory as a novel application of the methodology to assess 
patient reported outcome measures [11], identifying a concise list of 11 items from an 
original 45 questions that capture the majority of information distinguishing people with 
high distress. Disease distress correlated with percent predicted lung function and could 
characterise disease progression. Furthermore, scores could predict mortality with those 
scoring highest also at greatest risk of death. The associations of disease distress with 
lung function, disease progression and mortality support the IPARC Score as a valid tool 
to inform prognoses.  
Previous studies using alternate patient reported outcomes to measure quality of life in 
IPF have similarly noted weak to moderate correlations with lung function measures, 
including the MRC dyspnoea scale, ATAQ-IPF and CAT [25-27]. Imperfect correlations 
indicate that lung function alone cannot account for all differences in patient reported 
outcomes, in combination they offer tremendous clinical value [28]. However, the MRC 
dyspnoea scale is one dimensional, ATAQ-IPF remains extensive at 75 items and CAT 
was developed for COPD, which at 8 items is convenient but may not have the sensitivity 
to capture IPF traits [29]. Whilst the original SPARC is a broad palliative assessment 
survey, answers provided by an IPF population specify appropriate items in the IPARC 
tool. The unabbreviated name, IPF Prognostic Assessment and Referral to Care, reflects 
the purpose and cohort it was developed with, as well as the tool it originated from. 
Strengths and limitations of Item Response Theory application 
IRT is an increasingly applied methodology that lends itself to parametric tests, providing 
an evidence base for reusing questions that can be used to distinguish traits of interest 
[16, 18, 30]. This study supports the use of IRT methodology in optimising questions 
within healthcare surveys to predict patient outcomes. Questions that did not distinguish 
levels of distress, such as those which scored low for the vast majority (e.g. Q33: 
Religious or spiritual needs not being met), or those that can show clustering of 
responses (e.g. Q30: Thoughts about ending it all; Q32: Worrying thoughts about death 
or dying) can be dropped in order to retain items offering the most discriminatory value.  
IRT methodology can also assess the way in which an item may be answered differently 
according to demographic traits that are unrelated to the latent trait of distress, termed 
differential item functioning (DIF)[16, 17]. We identified no DIF in the final model 
according to gender, indicating men and women with IPF report distress similarly. Of the 
243 individuals sampled in this study two were of non-white origin, and thus we were 
not able to assess the influence of ethnicity on patient responses. Further study in more 
ethnically diverse populations is warranted to determine whether IPARC retains 
prognostic value. DIF by demographics of age category and comorbidity count was 
identified for item 21 (Feeling restless and agitated), however the analyses indicate an 
underlying relationship between these demographics and disease distress, so are not 
defined as DIF. The original SPARC questionnaire collects distress information from an 
extensive list of possible issues, with a response of ‘very much’ (score of 3) in any of the 
41 scaled items acting as a flag that the individual would benefit from an immediate 
palliative care assessment. Within clinical settings, the SPARC questionnaire could be 
considered too sensitive, or excessive depending on health status [6, 9], whilst under-
reporting of distress is an issue in progressive disease [10, 31]. Use of the cumulative 
score over 11 items provides greater opportunity to capture distress when under-
reported, whilst shorter health questionnaires can provide similar insight to lengthier 
ones [32]. 
The mean distress for those with lowest %DLCO equated to a score of 9.1, with a score 
of 9 being subsequently used as a threshold point for grouping people who may undergo 
disease progression within one year. Lung function measures are a valuable tool in 
defining disease progression, although limited by the scheduling of measurement 
recordings that may not reflect the actual timing of progression. Those who progressed 
had an average score of 8.8, which supports an IPARC Score of 9 as a suitable 
benchmark, particularly as those who died had an average score of 10.2.  
Other self-reported surveys exist to measure health status in those with progressive lung 
disease, including King’s-Brief Interstitial Lung Disease (K-BILD) questionnaire[15]. The 
authors of K-BILD used patient interviews to define a series of pertinent questions and 
Rasch analysis to refine the item list to 15 with 4 domains and a 7-point Likert scale. We 
use similar methodology to refine the list of predetermined SPARC items, as answered 
by a sample of 243 IPF patients, to a set of 11 within a single domain and a 4-point 
Likert scale. Whilst K-BILD offers an empowering way to self-monitor respiratory health, 
IPARC should be completed within clinical settings where rapid disease progression is a 
factor. 
IPARC Score offers prognosis estimates for clinical decisions 
ROC analysis confirmed that %DLCO was the best measure for predicting one year 
mortality in this cohort [33]. IPARC Score appeared to perform slightly better at 
identifying true positives compared with %FVC when the accepted proportion of false 
positives was restricted to 50%. Lung function measurements can be challenging for 
patients with severe disease to provide, and this appears particularly apparent in people 
missing DLCO who were significantly more distressed than those without missing DLCO 
values. These data illustrate the considerable survival bias associated with lung function 
data in studies of patients with progressive lung disease. As a result, these analyses may 
underestimate IPARC performance relative to lung function measures, yet demonstrate 
the value of patient-reported measures. 
Therapy modified quality of life measures can inform whether an intervention is 
necessary or successful [34]. We undertook a preliminary analysis on a very small 
subset of patients, which indicated that treatment with pirfenidone in patients with mild 
levels of distress may be associated with increased levels of distress following anti-
fibrotic therapy. This is consistent with the known adverse effect profile of pirfenidone 
though we do not account for clinical presentation or disease progression on therapy. We 
recommend further trials measure distress modification following therapeutic 
intervention to assess whether IPARC can be used to define individuals for whom a 
particular therapy may be heightening distress. 
Survival curves indicated that whilst the majority of the cohort survived one year after 
completing their SPARC questionnaire, those with the highest IPARC scores had poorer 
life expectancy than those scoring lowest. The positive predictive value of mortality in 
one year was 29% for those scoring above the threshold of 9, and increased to 43% for 
those scoring 19 or more.  The findings provide evidence that patient reported distress 
can predict early mortality with similar accuracy to predictions made with FVC lung 
function recordings.  
Adjusted survival analyses further show that risk of one-year mortality increased by 10% 
with each incremental point, whilst risk of progression increased by 5%. Intermediate 
scoring of 9 to 18 heightened the likelihood of progression and more than doubled the 
risk of death, compared to those scoring lower. It can be observed that a large 
proportion of the highest scorers did not survive beyond 105 days, although these 
estimates are based on low numbers. This relatively large sample of people with 
confirmed IPF supports the benefit of patient reported distress in predicting disease 
progression and death.   
Given that it is challenging to perform lung function in patients with progressive disease 
it is important to develop clinical markers of prognosis as well as assessing health status. 
The IPARC Score requires no specialist equipment or training to complete or calculate, 
takes consideration of the individual’s concerns, can be undertaken at any time without a 
requirement for repeated measures, and can aid decisions to review patients earlier. 
Combined with its associations with lung function and mortality, this patient-reported 
outcome is a potential component of composite endpoints in clinical trials, although 
further validation and studies on treatment sensitivity are essential [35]. The predictive 
capacity could not exclude all false positives, yet we recognise that early integration of 
palliative care can improve outcomes in other progressive diseases [3, 4, 36]. Future 
studies may include IPARC Score as part of a composite scoring system for accurately 
predicting IPF prognosis, adding value in treatment recommendations [33]. We 
recommend utilising it in combination with available lung function recordings when 
making clinical decisions (see Box 1).  
The simple practicality of the tool allows an assessment of factors impacting quality of 
life to identify appropriate clinical management strategies such as supplemental oxygen 
for those reporting high distress with shortness of breath, or domiciliary support and 
assistive living devices to reduce distress from losing independence. Where best 
supportive care is indicated through high score and clinical presentation, the tool 
encourages a focus on the most distressing features for the individual [28]. We welcome 
further study to validate the IPARC tool in separate cohorts of patients with progressive 
lung disease, including IPF.  
Conclusion 
The IPARC Score, developed using the SPARC holistic tool, offers an encouraging method 
to assess prognosis and recognise palliative care needs for those with progressive 
disease. In producing a standardised model based on the latent trait of distress for 
people with IPF, we generated an abridged list of items that could distinguish those who 
died within one year, with higher scores having worse prognosis. This brief and simple 
tool offers utility in the clinical care of patients with progressive lung fibrosis, whilst 
future study should address its validity following anti-fibrotic therapy and in other 
progressive lung diseases.  
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Figure 1. Negative correlation of distress with percent predicted lung function. 
A) Plotted %FVC against distress value generated from IPARC Score model resulted in a 
Pearson correlation coefficient (r) of -0.267 (p=0.0001) from 222 people (220 degrees 
freedom); %FVC explains 7.1% of variation in disease distress. B) Plotted Log 
transformed %DLCO against distress value resulted in r=-0.275 (p=0.0003) from 168 
people (166 degrees freedom); %DLCO explains 7.6% of variation in disease distress. 
Figure 2. Expected IPARC Scores from mean distress in lung function 
categories. Item response theory test characteristic curve from 11 items in final model 
plots distress (theta) values against expected score. Scale of theta has a mean of 0 and 
the arbitrary range (4) represents incremental standard deviations. A) Mean theta values 
plotted for %DLCO category: >60% (long dash), 40-60% (short dash), <40% (solid); i. 
one-way ANOVA p=0.006; ii. Post-hoc Tukey analysis p=0.004 <40 %DLCO compared 
with >60. B) Mean theta values plotted for disease progression: no progression (long 
dash), disease progression (solid); i. Two way t-test p=0.0085. Death only (short dash); 
ii. One-way ANOVA death, decline only, no decline p=0.003; iii. Post-hoc Tukey analysis 
p=0.002 death compared with no decline. 
Figure 3. Receiver-Operator Curve (ROC) assesses sensitivity and specificity of 
measures in predicting progression. A) Area under curve (AUC) for IPARC Score in 
predicting disease progression = 0.60 (95% confidence interval 0.53-0.68) B. AUC for 
IPARC Score (solid line) in predicting one year mortality =0.64 (0.52-0.77); %DLCO 
(long dash) AUC=0.83 (0.75-0.91); %FVC (short dash) AUC=0.66 (0.56-0.76). %DLCO 
AUC greater than IPARC AUC, p=0.013. 
Figure 4. Kaplan Meier analyses of time to event. A) Kaplan Meier Curves plot 
proportion of people with no disease progression against time since completing 
questionnaire: IPARC Score low (0-8, solid line), intermediate (8-18, dashed), high (9-
33, dotted). B) Kaplan Meier Curves plot proportion of people surviving against time 
since completing questionnaire: IPARC Score low (0-8, solid line), intermediate (8-18, 
dashed), high (9-33, dotted). 
